IMMX - Immix granted FDA nod to start U.S. trial for cell therapy
2023-11-21 11:47:03 ET
More on Immix Biopharma
- Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum
- Immix Biopharma climbs on upcoming ASH readout
- Immix gains FDA orphan drug status for CAR-T therapy
- Seeking Alpha’s Quant Rating on Immix Biopharma, Inc.
- Historical earnings data for Immix Biopharma, Inc.
For further details see:
Immix granted FDA nod to start U.S. trial for cell therapy